• metastatic/advanced RCC (mRCC) - 2nd line (L2) 1
• sarcomas
• thyroid cancer
• urothelial cancer (UC) - bladder cancer (BC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus SoC
• avelumab based treatment
• avelumab alone
• durvalumab based treatment
• durvalumab alone
• nivolumab based treatment
• nivolumab alone
• pembrolizumab based treatment
• pembrolizumab alone
• pembrolizumab plus SoC
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs platinum-based chemotherapy
• vs platinum derivate
• vs platinum association
• vs gemcitabine plus platin
• vs Standard of Care (SoC)
• vs placebo plus SoC
• vs non active control
• vs BSC
• vs no additional treatment
• vs no control (uncontrolled study)
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Pathology:  mUC - L1 - all population;   mUC - L1 - PDL1 positive;